POINT Biopharma Global Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.6
- Today's High:
- $7.9
- Open Price:
- $7.83
- 52W Low:
- $5.59
- 52W High:
- $11.13
- Prev. Close:
- $7.85
- Volume:
- 293279
Company Statistics
- Market Cap.:
- $863.05 million
- Book Value:
- 4.231
- Revenue TTM:
- $240.90 million
- Operating Margin TTM:
- 46.81%
- Gross Profit TTM:
- $0
- Profit Margin:
- 40.4%
- Return on Assets TTM:
- 19.25%
- Return on Equity TTM:
- 29.36%
Company Profile
POINT Biopharma Global Inc had its IPO on 2020-07-08 under the ticker symbol PNT.
The company operates in the Healthcare sector and Biotechnology industry. POINT Biopharma Global Inc has a staff strength of 129 employees.
Stock update
Shares of POINT Biopharma Global Inc opened at $7.83 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.6 - $7.9, and closed at $7.67.
This is a -2.29% slip from the previous day's closing price.
A total volume of 293,279 shares were traded at the close of the day’s session.
In the last one week, shares of POINT Biopharma Global Inc have slipped by -6%.
POINT Biopharma Global Inc's Key Ratios
POINT Biopharma Global Inc has a market cap of $863.05 million, indicating a price to book ratio of 2.2559 and a price to sales ratio of 0.
In the last 12-months POINT Biopharma Global Inc’s revenue was $240.90 million with a gross profit of $0 and an EBITDA of $114.90 million. The EBITDA ratio measures POINT Biopharma Global Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, POINT Biopharma Global Inc’s operating margin was 46.81% while its return on assets stood at 19.25% with a return of equity of 29.36%.
In Q2, POINT Biopharma Global Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
POINT Biopharma Global Inc’s PE and PEG Ratio
- Forward PE
- 62.8931
- Trailing PE
- 7.4182
- PEG
Its diluted EPS in the last 12-months stands at $1.1 per share while it has a forward price to earnings multiple of 62.8931 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into POINT Biopharma Global Inc’s profitability.
POINT Biopharma Global Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -8.6272. Its price to sales ratio in the trailing 12-months stood at 0.
POINT Biopharma Global Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $497.77 million
- Total Liabilities
- $41.16 million
- Operating Cash Flow
- $20.44 million
- Capital Expenditure
- $7.33 million
- Dividend Payout Ratio
- 0%
POINT Biopharma Global Inc ended 2024 with $497.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $497.77 million while shareholder equity stood at $447.45 million.
POINT Biopharma Global Inc ended 2024 with $0 in deferred long-term liabilities, $41.16 million in other current liabilities, 10576.00 in common stock, $-2933005.00 in retained earnings and $0 in goodwill. Its cash balance stood at $57.29 million and cash and short-term investments were $423.23 million. The company’s total short-term debt was $1,257,031 while long-term debt stood at $0.
POINT Biopharma Global Inc’s total current assets stands at $432.38 million while long-term investments were $11.57 million and short-term investments were $365.93 million. Its net receivables were $3.73 million compared to accounts payable of $13.90 million and inventory worth $5.20 million.
In 2024, POINT Biopharma Global Inc's operating cash flow was $20.44 million while its capital expenditure stood at $7.33 million.
Comparatively, POINT Biopharma Global Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.67
- 52-Week High
- $11.13
- 52-Week Low
- $5.59
- Analyst Target Price
- $16.1
POINT Biopharma Global Inc stock is currently trading at $7.67 per share. It touched a 52-week high of $11.13 and a 52-week low of $11.13. Analysts tracking the stock have a 12-month average target price of $16.1.
Its 50-day moving average was $8.63 and 200-day moving average was $8.07 The short ratio stood at 11.53 indicating a short percent outstanding of 0%.
Around 1533.6% of the company’s stock are held by insiders while 5976.5% are held by institutions.
Frequently Asked Questions About POINT Biopharma Global Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.